Raymond James Financial
KRYS icon

Raymond James Financial’s Krystal Biotech KRYS Stock Holding History

Raymond James Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59M Buy
158,675
+2,611
+2% +$780K 0.02% 846
2026
Q1 		$39.5M Buy
156,064
+79,526
+104% +$21.2M 0.01% 1004
2025
Q4 		$19M Buy
76,538
+12,175
+19% +$2.56M 0.01% 1485
2025
Q3 		$11.4M Sell
64,363
-4,372
-6% -$654K ﹤0.01% 1815
2025
Q2 		$9.45M Buy
68,735
+2,774
+4% +$407K ﹤0.01% 1918
2025
Q1 		$11.9M Sell
65,961
-36,100
-35% -$6.07M ﹤0.01% 1679
2024
Q4 		$16M Buy
+102,061
New +$18.1M 0.01% 1485

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raymond James Financial's KRYS Position: Q2 2026 in Review

Raymond James Financial increased its Krystal Biotech (KRYS) stake by 1.7% in Q2 2026, buying an estimated $780K and bringing the position to 158,675 shares worth $59M. The position accounts for 0.02% of the portfolio, ranked #846.

Raymond James Financial first reported a position in KRYS in Q4 2024 and has held it in 7 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Raymond James Financial held 158,675 shares of Krystal Biotech worth $59M as of Q2 2026.
  • Raymond James Financial bought 2,611 Krystal Biotech shares in Q2 2026, an estimated $780K.
  • Krystal Biotech made up 0.02% of Raymond James Financial's portfolio in Q2 2026, its #846 holding.
  • Raymond James Financial first reported a position in Krystal Biotech in Q4 2024 and has held it in 7 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.